Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Serum Uric Acid and Clinical Cardiovascular Diseases in Men and Women: A Perspective for the Drug Target and the Effect of Sex

Author(s): Pang-Yen Liu, Chen-Ming Huang, Han-Hsing Chen, Hui-Shang Wang and Gen-Min Lin*

Volume 23, Issue 11, 2023

Published on: 05 June, 2023

Page: [1368 - 1370] Pages: 3

DOI: 10.2174/1871530323666230505114734

Open Access Journals Promotions 2
« Previous Next »
[1]
van Durme, C.; van Echteld, I.A.A.M.; Falzon, L.; Aletaha, D.; van der Heijde, D.M.F.M.; Landewé, R.B. Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: A systematic review of the literature. J. Rheumatol. Suppl., 2014, 92(0), 9-14.
[http://dx.doi.org/10.3899/jrheum.140457] [PMID: 25180123]
[2]
Zhu, Y.; Pandya, B.J.; Choi, H.K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am. J. Med., 2012, 125(7), 679-687.e1.
[http://dx.doi.org/10.1016/j.amjmed.2011.09.033] [PMID: 22626509]
[3]
Lin, J.W.; Tsai, K.Z.; Chen, K.W.; Su, F.Y.; Li, Y.H.; Lin, Y.P.; Han, C.L.; Lin, F.; Lin, Y.K.; Hsieh, C.B.; Lin, G.M. Sex-specific association between serum uric acid and elevated alanine aminotransferase in a military cohort: The chief study. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(3), 333-340.
[http://dx.doi.org/10.2174/1871530319666181129163802] [PMID: 30499423]
[4]
Lin, Y.K.; Lin, Y.P.; Lee, J.T.; Lin, C.S.; Wu, T.J.; Tsai, K.Z.; Su, F.Y.; Kwon, Y.; Hoshide, S.; Lin, G.M. Sex-specific association of hyperuricemia with cardiometabolic abnormalities in a military cohort. Medicine (Baltimore), 2020, 99(12), e19535.
[http://dx.doi.org/10.1097/MD.0000000000019535] [PMID: 32195957]
[5]
Li, Y.H.; Lin, G.M.; Lin, C.L.; Wang, J.H.; Chen, Y.J.; Han, C.L. Relation of serum uric acid and body mass index to mortality in high-risk patients with established coronary artery disease: A report from the ET-CHD registry, 1997–2006. J. Cardiol., 2013, 62(6), 354-360.
[http://dx.doi.org/10.1016/j.jjcc.2013.06.002] [PMID: 23838556]
[6]
Li, B.; Chen, L.; Hu, X.; Tan, T.; Yang, J.; Bao, W.; Rong, S. Association of serum uric acid with all-cause and cardiovascular mortality in diabetes. Diabetes Care, 2023, 46(2), 425-433.
[http://dx.doi.org/10.2337/dc22-1339] [PMID: 36490263]
[7]
White, W.B.; Saag, K.G.; Becker, M.A.; Borer, J.S.; Gorelick, P.B.; Whelton, A.; Hunt, B.; Castillo, M.; Gunawardhana, L. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med., 2018, 378(13), 1200-1210.
[http://dx.doi.org/10.1056/NEJMoa1710895] [PMID: 29527974]
[8]
Kang, E.H.; Park, E.H.; Shin, A.; Song, J.S.; Kim, S.C. Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Eur. Heart J., 2021, 42(44), 4578-4588.
[http://dx.doi.org/10.1093/eurheartj/ehab619] [PMID: 34508567]
[9]
Kim, S.C.; Neogi, T.; Kang, E.H.; Liu, J.; Desai, R.J.; Zhang, M.; Solomon, D.H. Cardiovascular risks of probenecid versus allopurinol in older patients with gout. J. Am. Coll. Cardiol., 2018, 71(9), 994-1004.
[http://dx.doi.org/10.1016/j.jacc.2017.12.052] [PMID: 29496000]
[10]
Mackenzie, I.S.; Hawkey, C.J.; Ford, I.; Greenlaw, N.; Pigazzani, F.; Rogers, A.; Struthers, A.D.; Begg, A.G.; Wei, L.; Avery, A.J.; Taggar, J.S.; Walker, A.; Duce, S.L.; Barr, R.J.; Dumbleton, J.S.; Rooke, E.D.; Townend, J.N.; Ritchie, L.D.; MacDonald, T.M.; Ahmed, H.; Arthur, P.; Aziz, J.; Barnes, L.; Boyle, S.; Brighton, T.; Brown, M.; Caulfield, M.; Dawson, J.; Denvir, M.; Doney, A.S.F.; Doshi, S.; Dryburgh, M.; Eddleston, M.; Finlayson, J.; Fuat, A.; Furnace, J.; Grieve, J.W.K.; Guthrie, G.; Ham, S.; Isaard, E.; Jennings, C.; Johnson, R.; Kerr, C.; Khan, S.; Krishnan, K.; Long, S.; Mackintosh, A.; Macleod, M.J.; McCormack, T.; McEleny, P.; Morar, M.; Nadir, A.; Newby, D.; Petrie, C.; Preiss, D.; Ralston, S.; Randall, M.; Routledge, H.; Shakir, S.; Sharma, R.; Shepherd, B.; Sims, D.; Snedden, G.; Trevelyan, J.; Weir, C.; Weir, R.; Wetherall, K.; Wilson, R.; Wilson, A.; Zutis, K. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): A multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 2022, 400(10359), 1195-1205.
[http://dx.doi.org/10.1016/S0140-6736(22)01657-9] [PMID: 36216006]
[11]
Zanchi, A.; Pruijm, M.; Muller, M.E.; Ghajarzadeh-Wurzner, A.; Maillard, M.; Dufour, N.; Bonny, O.; Wuerzner, G.; Burnier, M. Twenty-four hour blood pressure response to empagliflozin and its determinants in normotensive non-diabetic subjects. Front. Cardiovasc. Med., 2022, 9, 854230.
[http://dx.doi.org/10.3389/fcvm.2022.854230] [PMID: 35391843]
[12]
Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C.P.; Capuano, G.; Chu, P.L.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B.M.; Mahaffey, K.W. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med., 2019, 380(24), 2295-2306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260]
[13]
Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Pocock, S.J.; Carson, P.; Januzzi, J.; Verma, S.; Tsutsui, H.; Brueckmann, M.; Jamal, W.; Kimura, K.; Schnee, J.; Zeller, C.; Cotton, D.; Bocchi, E.; Böhm, M.; Choi, D.J.; Chopra, V.; Chuquiure, E.; Giannetti, N.; Janssens, S.; Zhang, J.; Gonzalez Juanatey, J.R.; Kaul, S.; Brunner-La Rocca, H.P.; Merkely, B.; Nicholls, S.J.; Perrone, S.; Pina, I.; Ponikowski, P.; Sattar, N.; Senni, M.; Seronde, M.F.; Spinar, J.; Squire, I.; Taddei, S.; Wanner, C.; Zannad, F. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med., 2020, 383(15), 1413-1424.
[http://dx.doi.org/10.1056/NEJMoa2022190] [PMID: 32865377]
[14]
Requena-Ibáñez, J.A.; Santos-Gallego, C.G.; Rodriguez-Cordero, A.; Vargas-Delgado, A.P.; Mancini, D.; Sartori, S.; Atallah-Lajam, F.; Giannarelli, C.; Macaluso, F.; Lala, A.; Sanz, J.; Fuster, V.; Badimon, J.J. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF. JACC Heart Fail., 2021, 9(8), 578-589.
[http://dx.doi.org/10.1016/j.jchf.2021.04.014] [PMID: 34325888]
[15]
Barros, R.P.A.; Gustafsson, J.Å. Estrogen receptors and the metabolic network. Cell Metab., 2011, 14(3), 289-299.
[http://dx.doi.org/10.1016/j.cmet.2011.08.005] [PMID: 21907136]
[16]
Hak, A.E.; Choi, H.K. Menopause, postmenopausal hormone use and serum uric acid levels in US women – The Third National Health and Nutrition Examination Survey. Arthritis Res. Ther., 2008, 10(5), R116.
[http://dx.doi.org/10.1186/ar2519] [PMID: 18822120]
[17]
Liu, L.; Zhao, T.; Shan, L.; Cao, L.; Zhu, X.; Xue, Y. Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway. Nutr. Metab. (Lond.), 2021, 18(1), 63.
[http://dx.doi.org/10.1186/s12986-021-00583-y] [PMID: 34144706]
[18]
Cai, K.; Wu, B.; Mehta, S.; Harwood, M.; Grey, C.; Dalbeth, N.; Wells, S.M.; Jackson, R.; Poppe, K. Association between gout and cardiovascular outcomes in adults with no history of cardiovascular disease: Large data linkage study in New Zealand. BMJ Med., 2022, 1(1), e000081.
[http://dx.doi.org/10.1136/bmjmed-2021-000081]
[19]
Lin, G.M.; Li, Y.H.; Zheng, N.C.; Lai, C.P.; Lin, C.L.; Wang, J.H.; Jaiteh, L.E.S.; Han, C.L. Serum uric acid as an independent predictor of mortality in high-risk patients with obstructive coronary artery disease. J. Cardiol., 2013, 61(2), 122-127.
[http://dx.doi.org/10.1016/j.jjcc.2012.09.004] [PMID: 23088935]
[20]
Tsai, K.Z.; Liu, P.Y.; Huang, W.C.; Lima, J.A.C.; Lavie, C.J.; Lin, G.M. Sex-specific cardiometabolic risk markers of left ventricular mass in physically active young adults: The CHIEF heart study. Sci. Rep., 2022, 12(1), 11536.
[http://dx.doi.org/10.1038/s41598-022-15818-y] [PMID: 35798830]
[21]
Lin, Y.K.; Liu, P.Y.; Fan, C.H.; Tsai, K.Z.; Lin, Y.P.; Lee, J.M.; Lee, J.T.; Lin, G.M. Metabolic biomarkers and long-term blood pressure variability in military young male adults. World J. Clin. Cases, 2020, 8(11), 2246-2254.
[http://dx.doi.org/10.12998/wjcc.v8.i11.2246] [PMID: 32548155]
[22]
Higgins, P.; Walters, M.R.; Murray, H.M.; McArthur, K.; McConnachie, A.; Lees, K.R.; Dawson, J. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: A randomised controlled trial. Heart, 2014, 100(14), 1085-1092.
[http://dx.doi.org/10.1136/heartjnl-2014-305683] [PMID: 24790069]
[23]
Gaffo, A.L.; Calhoun, D.A.; Rahn, E.J.; Oparil, S.; Li, P.; Dudenbostel, T.; Feig, D.I.; Redden, D.T.; Muntner, P.; Foster, P.J.; Biggers-Clark, S.R.; Mudano, A.; Sattui, S.E.; Saddekni, M.B.; Bridges, S.L., Jr; Saag, K.G. Effect of serum urate lowering with allopurinol on blood pressure in young adults: A randomized, controlled, crossover trial. Arthritis Rheumatol., 2021, 73(8), 1514-1522.
[http://dx.doi.org/10.1002/art.41749] [PMID: 33779064]
[24]
Gingles, C.R.; Symon, R.; Gandy, S.J.; Struthers, A.D.; Houston, G.; MacDonald, T.M.; Lang, C.C.; Donnan, P.T.; George, J. Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension. J. Hypertens., 2019, 37(12), 2481-2489.
[http://dx.doi.org/10.1097/HJH.0000000000002189] [PMID: 31268872]
[25]
Rekhraj, S.; Gandy, S.J.; Szwejkowski, B.R.; Nadir, M.A.; Noman, A.; Houston, J.G.; Lang, C.C.; George, J.; Struthers, A.D. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J. Am. Coll. Cardiol., 2013, 61(9), 926-932.
[http://dx.doi.org/10.1016/j.jacc.2012.09.066] [PMID: 23449426]

Rights & Permissions Print Cite
Article Metrics
22
1
Wayfinder Image
Open Access Journals Promotions
World Diabetes Day
© 2024 Bentham Science Publishers | Privacy Policy